PW
Therapeutic Areas
DBV Technologies Pipeline
| Drug | Indication | Phase |
|---|---|---|
| VIASKIN® Peanut (DBV712) | Peanut Allergy (Children 4-7 years) | Phase 3 |
| VIASKIN® Milk (DBV135) | Cow's Milk Allergy | Phase 1/2 |
Leadership Team at DBV Technologies
DT
Daniel Tassé
Chief Executive Officer
PM
Pharis Mohideen
Chief Medical Officer
VB
Virginie Boucinha
Chief Financial Officer
KT
Kevin Trapp
Chief Commercial Officer
MF
Michele F. Robertson
Chief Legal Officer
JB
James Briggs
Chief Human Resources Officer
KP
Kevin P. Malobisky
Chief Operations Officer
RP
Robert Pietrusko
Chief Regulatory Officer
MD
Michel de Rosen
Chairman of the Board of Directors
HA
Hugh A. Sampson
Chairman of the Scientific Advisory Board